Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rizatriptan + caffeine is a hypothetical or investigational combination of two active ingredients used for the acute treatment of migraine headaches. Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist, commonly known as a "triptan," which works by constricting intracranial blood vessels, inhibiting neuropeptide release, and reducing transmission in the trigeminal pain pathway to relieve migraine symptoms[4][6]. Caffeine is a central nervous system stimulant that can enhance the effectiveness of certain analgesics and has vasoconstrictive properties. While combinations like aspirin/acetaminophen/caffeine are marketed for migraines (e.g., Excedrin Migraine), there are no approved or widely available pharmaceutical products combining rizatriptan with caffeine[1]. The rationale for such a combination would be to potentially improve efficacy in acute migraine relief by leveraging both mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rizatriptan + caffeine.